Literature DB >> 32936265

Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History.

Ahmad Masri1,2, Hongya Chen1,2, Catherine Wong1,2, Katherine L Fischer1,2, Chafic Karam2,3, Walid F Gellad4, Stephen B Heitner1,2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32936265      PMCID： PMC7301295          DOI： 10.1001/jamacardio.2020.1738

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  3 in total

1.  Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.

Authors:  Dhruv S Kazi; Brandon K Bellows; Suzanne J Baron; Changyu Shen; David J Cohen; John A Spertus; Robert W Yeh; Suzanne V Arnold; Brett W Sperry; Mathew S Maurer; Sanjiv J Shah
Journal:  Circulation       Date:  2020-02-12       Impact factor: 29.690

2.  Tafamidis-A Pricey Therapy for a Not-So-Rare Condition.

Authors:  Jerry H Gurwitz; Mathew S Maurer
Journal:  JAMA Cardiol       Date:  2020-03-01       Impact factor: 14.676

3.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Authors:  Mathew S Maurer; Jeffrey H Schwartz; Balarama Gundapaneni; Perry M Elliott; Giampaolo Merlini; Marcia Waddington-Cruz; Arnt V Kristen; Martha Grogan; Ronald Witteles; Thibaud Damy; Brian M Drachman; Sanjiv J Shah; Mazen Hanna; Daniel P Judge; Alexandra I Barsdorf; Peter Huber; Terrell A Patterson; Steven Riley; Jennifer Schumacher; Michelle Stewart; Marla B Sultan; Claudio Rapezzi
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245
  3 in total
  5 in total

1.  Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.

Authors:  Omar K Siddiqi; Yuliya Y Mints; John L Berk; Lawreen Connors; Gheorghe Doros; Deepa M Gopal; Shivangi Kataria; Graham Lohrmann; Alexandra R Pipilas; Frederick L Ruberg
Journal:  Amyloid       Date:  2022-01-27       Impact factor: 6.571

Review 2.  Targeted treatments of AL and ATTR amyloidosis.

Authors:  Pranav Chandrashekar; Anish K Desai; Barry H Trachtenberg
Journal:  Heart Fail Rev       Date:  2021-11-16       Impact factor: 4.654

3.  Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database.

Authors:  Anuja Roy; Andrew Peterson; Nick Marchant; Jose Alvir; Rahul Bhambri; Jason Lynn; Darrin Benjumea; Sapna Prasad; Alex O'Brien; Yong Chen; Jason Kemner; Bhash Parasuraman
Journal:  Patient Prefer Adherence       Date:  2022-04-29       Impact factor: 2.314

Review 4.  The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.

Authors:  Merilyn S Varghese; Chia-Liang Liu; Dhruv S Kazi
Journal:  Curr Cardiol Rep       Date:  2021-10-01       Impact factor: 2.931

Review 5.  Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer.

Authors:  Hongya Chen; Pranav Chandrashekar; Katherine Fischer; Dayna Carlson; Urja Narayan; Jack Chen; Ahmad Masri
Journal:  J Am Heart Assoc       Date:  2022-03-18       Impact factor: 5.501
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.